Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02977013Completed

Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism

Role: lead

NCT02795065Not ApplicableCompleted

Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients

Role: lead

NCT02764723Not ApplicableCompleted

Isobaric Spinal Ropivacaine Versus Hyperbaric Spinal Bupivacaine in Total Knee Arthroplasty in Geriatric Patients

Role: lead

NCT02754921Not ApplicableCompleted

Percutaneous Dilatational Tracheostomy: Ultra-perc Versus Ciaglia Blue Dolphin

Role: lead

All 4 trials loaded